Target Validation Information
TTD ID	T45758
Target Name	CD40L receptor (CD40)
Type of Target	Clinical trial
Action against Disease Model	Dacetuzumab	Drug Info	Dacetuz uMab activates two distinct proapoptotic signaling pathways, overcoming transformation events key to the pathogenesis of NHL. Dacetuz uMab-mediated CD40 signaling constitutively activated the nuclear factor-|?B and mitogen-activated protein kinase signaling pathways producing the sustained downregulation of B-cell lymphoma 6 (BCL-6), an oncoprotein implicated in lymphomagenesis. Loss of BCL-6 resulted in c-Myc downregulation and activation of a transcriptional program characteristic of early B-cell maturation, concomitant with reduced proliferation and cell death.	[1]
References
REF 1	Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia. 2011 Jun;25(6):1007-16.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.